公司资料
Kezar Life Sciences 股价、新闻与催化剂
- 股票代码:
- KZR
- 交易所:
- NASDAQ
- 行业:
- Life Science Tools
- 所在地:
- United States
股票表现
7.29 USD (-0.95%)
收盘价
最后更新: 2026年5月8日
53.9M USD
市值
股价为何变动
Current closing-price context is not available for KZR.
公司概览
业务概览
Kezar Life Sciences is a biotechnology company focused on immune pathways in autoimmune disease and oncology. Its strategy has centered on selective small-molecule biology and translational proof.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Kezar sits in specialty biotechnology.
商业模式特征
The business depends on clinical data, target validation, and the possibility of building a differentiated immune-modulation platform.
生物医药行业定位
Kezar is a catalyst-sensitive immunology name whose stock is driven by proof-of-concept and strategic updates.
未来催化剂
- Kezar’s catalysts are zetomipzomib and the remaining immunology pipeline, where the next update matters because the market needs a clearer read on what still has value. The company is in a reset phase, so strategic clarity matters as much as data.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。